European Health Examination Survey

https://neurodegenerationresearch.eu/survey/european-health-examination-survey/

Title of the cohort

European Health Examination Survey

Acronym for cohort

LUX-EHES

Name of Principal Investigator

Title	mme
First name	Marie-Lise
Last name	LAIR

Address of institution where award is held

Institution	
Street Address	1A-B rue Thomas Edison
City	SRASSEN
Postcode	L-1445

Country

Luxembourg

Website

www.crp-sante.lu

Contact email

marie-lise.lair@crp-sante.lu

Funding source

Health Ministry
Research Ministry

1. The cohort includes, or expects to include, incidence of the following conditions

- Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

2011 – 2015

2a. Stated aim of the cohort

to study public health determinants

2b. Features distinguishing this cohort from other population cohorts

we ask blood sample for biobanking

3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort

epdemiological informations public health informations impact of environmental conditions on health and some diseases

4a. Study criteria: age range of participants at recruitment

Age in years from: more 18 years

To ('until death' if applicable): 65 years

4b. Study criteria: inclusion criteria

criteria from european health examination survey will be used. People will be randomly selected from the national register.

4c. Study criteria: exclusion criteria

institutionalised people

5. Size of the cohort (i.e. number of participants enrolled)

5,001 – 10,000 participants

6a. Measures used to characterise participants

age, gender, comorbidities, socio economic conditions, socio educative conditions, environmental conditions, lifestyle (tobacco, nutrition, alcoohol, physical activity), medications, diseases, health status, family diseases, use of healthcare, ethnical informations, work conditions, vaccines, anthropometric measurements, blood pressure, blood analysis, visual capacity, auditiv capacity, cognitiv status

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

No

7. Study design

Cross sectional survey

8. Cases matched by

- Age
- Sex
- Co-morbidities
- Cognitive function
- Physical ability

9a. Does the study include a specialised subset of control participants

No

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-01-2012

10a. ii) Data collection end date

31-12-2013

10a iii) Data collection for this study is

- At the planning stage

10b. Plans to continue the cohort study beyond the current projected end date

- Yes – intend to apply for funding

11. Data collected

- Only through the study

12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

	Yes/No % available
Data summarised in database	yes
Database is web-based	yes
Database on spreadsheet	
Database is on paper	
Other (specify)	

Language used:

french, german, english, portuges

13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Apply to PI or co-ordinator at resource
- Access through collaboration with PI only
- Access Committee mechanism
- Local/ regional access
- National access
- International access
- Access restricted to peer-reviewed work
- Applicant needs to provide separate external ethics approval

15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA

- Living donors:blood
- Living donors: blood derivatives
- Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

No